Top

Published in:

Open Access 01-12-2020 | Lung Cancer | Research

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Authors: Li Qiao, Deliang Ma, Hui Lv, Ding Shi, Min Fei, Yu Chen, Fei Xie, Zhuoyan Wang, Ying Wang, Wanhua Liang, Peiying Hu

Published in: Diabetology & Metabolic Syndrome | Issue 1/2020

Abstract

Background

Metabolic syndrome (MetS) has been related to the pathogenesis of variety categories of cancers. This meta-analysis aimed to determine the association between MetS and the incidence of lung cancer.

Methods

Relevant cohort studies were identified by search of PubMed, Embase, and Cochrane’s Library databases. Cochrane’s Q test and I² statistic were used to analyze the heterogeneity. Random-effect model which incorporates the potential heterogeneity was used for the meta-analysis.

Results

Five cohort studies with 188,970 participants were included. A total of 1,295 lung cancer cases occurred during follow-up. Meta-analyses showed that neither MetS defined by the revised NCEP-ATP III criteria (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.84 to 1.05, p = 0.25; I² = 0) nor the IDF criteria (HR: 0.82, 95% CI: 0.61 to 1.11, p = 0.20; I² = 0) was associated with an affected risk of lung cancer. Subgroup analyses showed consistent results in women and in men, in studies performed in Asian and non-Asian countries, and in prospective and retrospective cohorts (p all > 0.05). Meta-analysis limited to studies with the adjustment of smoking status also showed similar results (HR: 0.91, 95% CI: 0.80 to 1.05, p = 0.21; I² = 0). No publication bias was detected based on the Egger regression test (p = 0.32).

Conclusions

Current evidence from cohort studies does not support that MetS is an independent risk factor for the incidence of lung cancer.

Kumari R, Kumar S, Kant R. An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr. 2019;13(4):2409–17. https://doi.org/10.1016/j.dsx.2019.06.005.CrossRef

He YN, Zhao WH, Zhao LY, Yu DM, Zhang J, Yang XG, Ding GG. Prevalence of metabolic syndrome in Chinese adults in 2010–2012. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(2):212–5. https://doi.org/10.3760/cma.j.issn.0254-6450.2017.02.015.CrossRef

Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, Qiu S, Cheng Y, Liu Y. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016;16:296. https://doi.org/10.1186/s12889-016-2870-y.CrossRef

Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629–36. https://doi.org/10.1161/ATVBAHA.107.151092.CrossRef

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32. https://doi.org/10.1016/j.jacc.2010.05.034.CrossRef

Li X, Fang F, Fu X, Lin H, Gao Q. Is Metabolic Syndrome Associated with the Risk of Recurrent Stroke: A Meta-Analysis of Cohort Studies. J Stroke Cerebrovasc Dis. 2017;26(12):2700–5. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.03.014.CrossRef

Ageno W, Di Minno MN, Ay C, Jang MJ, Hansen JB, Steffen LM, Vaya A, Rattazzi M, Pabinger I, Oh D, Di Minno G, Braekkan SK, Cushman M, Bonet E, Pauletto P, Squizzato A, Dentali F. Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysis. Arterioscler Thromb Vasc Biol. 2014;34(11):2478–85. https://doi.org/10.1161/ATVBAHA.114.304085.CrossRef

Xu S, Wan Y, Xu M, Ming J, Xing Y, An F, Ji Q. The association between obstructive sleep apnea and metabolic syndrome: a systematic review and meta-analysis. BMC Pulm Med. 2015;15:105. https://doi.org/10.1186/s12890-015-0102-3.CrossRef

Zhou J, Zhang Q, Yuan X, Wang J, Li C, Sheng H, Qu S, Li H. Association between metabolic syndrome and osteoporosis: a meta-analysis. Bone. 2013;57(1):30–5. https://doi.org/10.1016/j.bone.2013.07.013.CrossRef

10.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J. Jemal A (2015) Global cancer statistics. CA Cancer J Clin. 2012;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRef

11.

O'Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8(10):e021611. https://doi.org/10.1136/bmjopen-2018-021611.CrossRef

12.

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11. https://doi.org/10.2337/dc12-0336.CrossRef

13.

Leisegang K, Henkel R, Agarwal A. Obesity and metabolic syndrome associated with systemic inflammation and the impact on the male reproductive system. Am J Reprod Immunol. 2019;82(5):e13178. https://doi.org/10.1111/aji.13178.CrossRef

14.

Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol. 2012;32(8):1766–70. https://doi.org/10.1161/ATVBAHA.111.241927.CrossRef

15.

Uzunlulu M, Telci Caklili O, Oguz A. Association between Metabolic Syndrome and Cancer. Ann Nutr Metab. 2016;68(3):173–9. https://doi.org/10.1159/000443743.CrossRef

16.

Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 2009;45(10):1831–8. https://doi.org/10.1016/j.ejca.2009.01.031.CrossRef

17.

Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293–7. .CrossRef

18.

Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, Tsugane S. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18(3):240–7. https://doi.org/10.1097/CEJ.0b013e3283240460.CrossRef

19.

Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012;36(2):141–7. https://doi.org/10.1016/j.canep.2011.03.007.CrossRef

20.

van Kruijsdijk RC, van der Graaf Y, Peeters PH, Visseren FL. Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. Cancer Epidemiol Biomarkers Prev. 2013;22(7):1267–77. https://doi.org/10.1158/1055-9965.EPI-13-0090.CrossRef

21.

Ko S, Yoon SJ, Kim D, Kim AR, Kim EJ, Seo HY. Metabolic Risk Profile and Cancer in Korean Men and Women. J Prev Med Public Health. 2016;49(3):143–52. https://doi.org/10.3961/jpmph.16.021.CrossRef

22.

Gathirua-Mwangi WG, Monahan PO, Murage MJ, Zhang J. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control. 2017;28(2):127–36. https://doi.org/10.1007/s10552-016-0843-1.CrossRef

23.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–122.CrossRef

24.

Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration https://www.cochranehandbook.org

25.

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

26.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.CrossRef

27.

Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148–57. https://doi.org/10.1093/ije/dyn065.CrossRef

28.

Amos CI, Hung R, Bosse Y, Christiani DC, Field JK, Landi MT, Brennan PB, McKay JP (2016) P1.04: Defining the Genetic Architecture of Lung Cancer Etiology: Track: Prevention, Early Detection, Epidemiology and Tobacco Control. J Thorac Oncol 11 (10S):S182. https://doi.org/10.1016/j.jtho.2016.08.026

29.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.CrossRef

30.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39. https://doi.org/10.1161/01.CIR.0000133317.49796.0E.CrossRef

31.

Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469–80. https://doi.org/10.1111/j.1464-5491.2006.01858.x.CrossRef

32.

Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, Jiao Y. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer. 2013;132(5):1162–9. https://doi.org/10.1002/ijc.27719.CrossRef

33.

Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, Lu J, Sun X. A meta-analysis of body mass index and the risk of lung cancer in the Chinese population. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49(7):649–53.

34.

Hidayat K, Du X, Chen G, Shi M, Shi B. Abdominal Obesity and Lung Cancer Risk: Systematic Review and Meta-Analysis of Prospective Studies. Nutrients. 2016;8:12. https://doi.org/10.3390/nu8120810.CrossRef

35.

Gao J, Lin X, He Y, Fu Y, Wu Y, Liao J, Lian X. The Comparison of Different Obesity Indexes and the Risk of Lung Cancer: A Meta-Analysis of Prospective Cohort Studies. Nutr Cancer. 2019;71(6):908–21. https://doi.org/10.1080/01635581.2019.1595037.CrossRef

36.

Lin X, Lu L, Liu L, Wei S, He Y, Chang J, Lian X. Blood lipids profile and lung cancer risk in a meta-analysis of prospective cohort studies. J Clin Lipidol. 2017. https://doi.org/10.1016/j.jacl.2017.05.004.CrossRef

37.

Hao B, Yu M, Sang C, Bi B, Chen J. Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study. Lipids Health Dis. 2018;17(1):278. https://doi.org/10.1186/s12944-018-0925-z.CrossRef

38.

Lyu Z, Li N, Wang G, Feng X, Chen S, Su K, Li F, Wei L, Li X, Xie S, Guo L, Chen Y, Tan F, Yin J, Cui H, Chen H, Li J, Ren J, Shi J, Wu S, Dai M, He J. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. Int J Cancer. 2019;144(12):2972–84. https://doi.org/10.1002/ijc.32051.CrossRef

39.

Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G, Tretli S, Concin H, Engeland A, Jonsson H, Stattin P. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012;59(4):802–10. https://doi.org/10.1161/HYPERTENSIONAHA.111.189258.CrossRef

40.

Lee SY, Kim MT, Jee SH, Im JS. Does hypertension increase mortality risk from lung cancer? A prospective cohort study on smoking, hypertension and lung cancer risk among Korean men. J Hypertens. 2002;20(4):617–22.CrossRef

41.

Wang Z, Bao C, Su C, Xu W, Luo H, Chen L, Qi X. Association between diabetes or antidiabetic therapy and lung cancer: A meta-analysis. J Diabetes Investig. 2013;4(6):659–66. https://doi.org/10.1111/jdi.12112.CrossRef

42.

Park HJ, Joh HK, Choi S, Park SM. Type 2 diabetes mellitus does not increase the risk of lung cancer among never-smokers: a nationwide cohort study. Transl Lung Cancer Res. 2019;8(6):1073–7. https://doi.org/10.21037/tlcr.2019.11.01.CrossRef

43.

Xiao K, Liu F, Liu J, Xu J, Wu Q, Li X. The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: a meta-analysis. J Clin Pharm Ther. 2020. https://doi.org/10.1111/jcpt.13167.CrossRef

Title: Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies
Authors: Li Qiao
Deliang Ma
Hui Lv
Ding Shi
Min Fei
Yu Chen
Fei Xie
Zhuoyan Wang
Ying Wang
Wanhua Liang
Peiying Hu
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Published in: Diabetology & Metabolic Syndrome / Issue 1/2020
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-020-00598-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

High anxiety and depressive symptoms in partners of type 1 diabetes persons in a sample of the Brazilian population

Quality of life after gastric bypass surgery in patients with type 2 diabetes: patients’ experiences during 2 years of follow-up

Correction to: Microencapsulation of cellular aggregates composed of differentiated insulin and glucagon-producing cells from human mesenchymal stem cells derived from adipose tissue

Metabolic syndrome is associated with better quality of sleep in the oldest old: results from the “Mugello Study”

Inverse associations between serum urate and glycemic status in a general population and in persons with diabetes mellitus

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials